A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients

  1. García-Torralba, E.
  2. Navarro Manzano, E.
  3. Luengo-Gil, G.
  4. De la Morena Barrio, P.
  5. Chaves Benito, A.
  6. Pérez-Ramos, M.
  7. Álvarez-Abril, B.
  8. Ivars Rubio, A.
  9. García-Garre, E.
  10. Ayala de la Peña, F.
  11. García-Martínez, E.
Journal:
Frontiers in Oncology

ISSN: 2234-943X

Year of publication: 2023

Volume: 13

Type: Article

DOI: 10.3389/FONC.2023.1182725 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus